GuruFocus Premium Membership

Serving Intelligent Investors since 2004. Only 96 cents a day.

Free Trial

Free 7-day Trial
All Articles and Columns »

Wasatch International Growth Fund Comments on Abcam

June 05, 2014 | About:
Holly LaFon

Holly LaFon

255 followers
Abcam (LSE:ABC) is a web-based retailer of research antibodies. Like Oxford Instruments, a large portion of Abcam’s revenues depends on public funding for research. While public research funding trends seem to have stabilized, Abcam will be investing heavily to increase its portfolio of products and expand geographically. This will result in lower growth rates than the company has achieved historically. Given the recent sell-off in Abcam’s stock, its leading market position, and strong business model, we believe the market is presenting us with a buying opportunity.

From Wasatch International Growth (Trades, Portfolio) Fund's first quarter 2014 commentary.


Rating: 0.0/5 (0 votes)

Comments

Please leave your comment:


Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK